{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T23:33:00Z","timestamp":1791502380367,"version":"4.3.4"},"reference-count":130,"publisher":"Centers for Disease Control MMWR Office","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["MMWR Recomm. Rep."],"DOI":"10.15585\/mmwr.rr7101a1","type":"journal-article","created":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T13:45:41Z","timestamp":1661435141000},"page":"1-28","source":"Crossref","is-referenced-by-count":276,"title":["Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices \u2014 United States, 2022\u201323 Influenza Season"],"prefix":"10.15585","volume":"71","author":[{"given":"Lisa A.","family":"Grohskopf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenee H.","family":"Blanton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill M.","family":"Ferdinands","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessie R.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen R.","family":"Broder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Keipp","family":"Talbot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca L.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia M.","family":"Fry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6224","published-online":{"date-parts":[[2022,8,26]]},"reference":[{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R1","doi-asserted-by":"publisher","first-page":"761","DOI":"10.2105\/AJPH.76.7.761","article-title":"Excess pneumonia and influenza associated hospitalization during influenza epidemics in the United States, 1970\u201378.","volume":"76","author":"Barker","year":"1986","journal-title":"Am J Public Health"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R2","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1093\/oxfordjournals.aje.a113052","article-title":"Impact of epidemic type A influenza in a defined adult population.","volume":"112","author":"Barker","year":"1980","journal-title":"Am J Epidemiol"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/irv.12504","article-title":"Risk factors for serious outcomes associated with influenza illness in high- versus low- and middle-income countries: systematic literature review and meta-analysis.","volume":"12","author":"Coleman","year":"2018","journal-title":"Influenza Other Respir Viruses"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R4","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.vaccine.2006.09.041","article-title":"Influenza- and RSV-associated hospitalizations among adults.","volume":"25","author":"Mullooly","year":"2007","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R5","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1542\/peds.2012-1255","article-title":"The burden of influenza in young children, 2004\u20132009.","volume":"131","author":"Poehling","year":"2013","journal-title":"Pediatrics"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1056\/NEJMoa054869","article-title":"The underrecognized burden of influenza in young children.","volume":"355","author":"Poehling","year":"2006","journal-title":"N Engl J Med"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R7","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1001\/jama.2010.479","article-title":"Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States.","volume":"303","author":"Siston","year":"2010","journal-title":"JAMA"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R8","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/irv.12506","article-title":"Effects of seasonal and pandemic influenza on health-related quality of life, work and school absence in England: results from the Flu Watch cohort study.","volume":"12","author":"Fragaszy","year":"2018","journal-title":"Influenza Other Respir Viruses"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R9","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1097\/JOM.0000000000001120","article-title":"Influenza and workplace productivity loss in working adults.","volume":"59","author":"Van Wormer","year":"2017","journal-title":"J Occup Environ Med"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R10","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/irv.12604","article-title":"The impact of influenza infection on young children, their family and the health care system.","volume":"13","author":"Willis","year":"2019","journal-title":"Influenza Other Respir Viruses"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R11","first-page":"1","article-title":"Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010.","volume":"59","author":"Fiore","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R12","unstructured":"CDC. How flu vaccine effectiveness and efficacy are measured: questions and answers. Atlanta, GA: US Department of Health and Human Services, CDC; 2016. https:\/\/www.cdc.gov\/flu\/vaccines-work\/effectivenessqa.htm"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R13","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/irv.12486","article-title":"Annual estimates of the burden of seasonal influenza in the United States: a tool for strengthening influenza surveillance and preparedness.","volume":"12","author":"Rolfes","year":"2018","journal-title":"Influenza Other Respir Viruses"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R14","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1093\/cid\/ciz075","article-title":"Effects of influenza vaccination in the United States during the 2017\u20132018 influenza season.","volume":"69","author":"Rolfes","year":"2019","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R15","unstructured":"CDC. 2020\u201321 flu season summary FAQ. Atlanta, GA: US Department of Health and Human Services, CDC; 2021. https:\/\/www.cdc.gov\/flu\/season\/faq-flu-season-2020-2021.htm"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R16","unstructured":"CDC. Fluview. Weekly influenza surveillance report. Atlanta, GA: US Department of Health and Human Services, CDC; 2021. https:\/\/www.cdc.gov\/flu\/weekly\/index.htm"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr7005a1","article-title":"Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices, United States, 2021\u201322 influenza season.","volume":"70","author":"Grohskopf","year":"2021","journal-title":"MMWR Recomm Rep"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R18","unstructured":"Ahmed F. ACIP handbook for developing evidence-based recommendations, Version 1.2. Atlanta, GA: US Department of Health and Human Services, CDC; 2013."},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R19","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.vaccine.2014.06.052","article-title":"Waning vaccine protection against influenza A (H3N2) illness in children and older adults during a single season.","volume":"33","author":"Belongia","year":"2015","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R20","doi-asserted-by":"publisher","first-page":"3907","DOI":"10.1016\/j.vaccine.2016.05.034","article-title":"Influenza vaccine effectiveness: maintained protection throughout the duration of influenza seasons 2010\u20132011 through 2013\u20132014.","volume":"34","author":"Radin","year":"2016","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R21","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1093\/cid\/ciy770","article-title":"Intraseason waning of influenza vaccine effectiveness.","volume":"68","author":"Ray","year":"2019","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R22","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1093\/jpids\/piz077","article-title":"Influenza vaccine effectiveness among children for the 2017\u20132018 season.","volume":"9","author":"Powell","year":"2020","journal-title":"J Pediatric Infect Dis Soc"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R23","doi-asserted-by":"publisher","first-page":"20388","DOI":"10.2807\/ese.18.05.20388-en","article-title":"Decline in influenza vaccine effectiveness with time after vaccination, Navarre, Spain, season 2011\/12.","volume":"18","author":"Castilla","year":"2013","journal-title":"Euro Surveill"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R24","doi-asserted-by":"publisher","first-page":"20390","DOI":"10.2807\/ese.18.05.20390-en","article-title":"Low and decreasing vaccine effectiveness against influenza A(H3) in 2011\/12 among vaccination target groups in Europe: results from the I-MOVE multicentre case-control study.","volume":"18","author":"Kissling","year":"2013","journal-title":"Euro Surveill"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R25","first-page":"544","article-title":"Intraseason waning of influenza vaccine protection: evidence from the US Influenza Vaccine Effectiveness Network, 2011\u201312 through 2014\u201315.","volume":"64","author":"Ferdinands","year":"2017","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R26","doi-asserted-by":"publisher","first-page":"5799","DOI":"10.1016\/j.vaccine.2017.09.035","article-title":"Waning protection of influenza vaccination during four influenza seasons, 2011\/2012 to 2014\/2015.","volume":"35","author":"Puig-Barber\u00e0","year":"2017","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R27","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2016.21.16.30201","article-title":"I-MOVE multicentre case-control study 2010\/11 to 2014\/15: is there within-season waning of influenza type\/subtype vaccine effectiveness with increasing time since vaccination?","volume":"21","author":"Kissling","year":"2016","journal-title":"Euro Surveill"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R28","doi-asserted-by":"publisher","first-page":"20389","DOI":"10.2807\/ese.18.05.20389-en","article-title":"Vaccine effectiveness of 2011\/12 trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: evidence of waning intra-seasonal protection.","volume":"18","author":"Pebody","year":"2013","journal-title":"Euro Surveill"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R29","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1016\/j.vaccine.2019.03.054","article-title":"Evaluating the effectiveness of the influenza vaccine during respiratory outbreaks in Singapore\u2019s long term care facilities, 2017.","volume":"37","author":"Ng","year":"2019","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R30","doi-asserted-by":"publisher","first-page":"e299","DOI":"10.1017\/S0950268820002952","article-title":"Influenza vaccine failure in the tropics: a retrospective cohort study of waning effectiveness.","volume":"148","author":"Young","year":"2020","journal-title":"Epidemiol Infect"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R31","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.3390\/ijerph18031129","article-title":"Influenza vaccine effectiveness and waning effect in hospitalized older adults. Valencia Region, Spain, 2018\/2019 season.","volume":"18","author":"Mira-Iglesias","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R32","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1093\/cid\/ciab045","article-title":"Waning vaccine effectiveness against influenza-associated hospitalizations among adults, 2015\u20132016 to 2018\u20132019, United States Hospitalized Adult Influenza Vaccine Effectiveness Network.","volume":"73","author":"Ferdinands","year":"2021","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R33","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1056\/NEJMoa1401480","article-title":"Influenza vaccination of pregnant women and protection of their infants.","volume":"371","author":"Madhi","year":"2014","journal-title":"N Engl J Med"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R34","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/S1473-3099(16)30054-8","article-title":"Maternal immunisation with trivalent inactivated influenza vaccine for prevention of influenza in infants in Mali: a prospective, active-controlled, observer-blind, randomised phase 4 trial.","volume":"16","author":"Tapia","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R35","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/S1473-3099(17)30252-9","article-title":"Year-round influenza immunisation during pregnancy in Nepal: a phase 4, randomised, placebo-controlled trial.","volume":"17","author":"Steinhoff","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R36","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1056\/NEJMoa0708630","article-title":"Effectiveness of maternal influenza immunization in mothers and infants.","volume":"359","author":"Zaman","year":"2008","journal-title":"N Engl J Med"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R37","unstructured":"CDC. The flu season. Atlanta, GA: US Department of Health and Human Services, CDC; 2015. https:\/\/www.cdc.gov\/flu\/about\/season\/flu-season.htm"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R38","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1093\/infdis\/jix632","article-title":"Duration of influenza vaccine effectiveness: a systematic review, meta-analysis, and meta-regression of test-negative design case-control studies.","volume":"217","author":"Young","year":"2018","journal-title":"J Infect Dis"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R39","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1093\/cid\/ciz452","article-title":"Waning of influenza vaccine protection: exploring the trade-offs of changes in vaccination timing among older adults.","volume":"70","author":"Ferdinands","year":"2020","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R40","first-page":"1","article-title":"Immunization of health-care personnel: recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"60","author":"Advisory Committee on Immunization Practices","year":"2011","journal-title":"MMWR Recomm Rep"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R41","first-page":"1","article-title":"Influenza vaccination of healthcare personnel: recommendations of the Healthcare Infection Control Practices Advisory Committee (HICPAC) and the Advisory Committee on Immunization Practices (ACIP).","volume":"55","author":"Pearson","year":"2006","journal-title":"MMWR Recomm Rep"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R42","unstructured":"Kroger A, Bahta L, Hunter P. General best practice guidelines for immunization: best practices guidance of the Advisory Committee on Immunization Practices (ACIP). https:\/\/www.cdc.gov\/vaccines\/hcp\/acip-recs\/general-recs\/index.html"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R43","unstructured":"Afluria Quadrivalent [Package Insert]. Parkville, Victoria, Australia: Seqirus; 2022."},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R44","unstructured":"Fluzone Quadrivalent [Package Insert]. Swiftwater, PA: Sanofi Pasteur; 2022."},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R45","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1086\/507309","article-title":"Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5\u20138-year-old children.","volume":"194","author":"Neuzil","year":"2006","journal-title":"J Infect Dis"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R46","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.jpeds.2006.06.036","article-title":"Influenza vaccine effectiveness in healthy 6- to 21-month-old children during the 2003\u20132004 season.","volume":"149","author":"Allison","year":"2006","journal-title":"J Pediatr"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R47","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1542\/peds.2005-0049","article-title":"Effectiveness of the 2003\u20132004 influenza vaccine among children 6 months to 8 years of age, with 1 vs 2 doses.","volume":"116","author":"Ritzwoller","year":"2005","journal-title":"Pediatrics"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R48","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1542\/peds.2007-3304","article-title":"Vaccine effectiveness against laboratory-confirmed influenza in children 6 to 59 months of age during the 2003\u20132004 and 2004\u20132005 influenza seasons.","volume":"122","author":"Eisenberg","year":"2008","journal-title":"Pediatrics"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R49","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1001\/archpediatrics.2010.192","article-title":"Maternal influenza vaccination and effect on influenza virus infection in young infants.","volume":"165","author":"Eick","year":"2011","journal-title":"Arch Pediatr Adolesc Med"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R50","doi-asserted-by":"publisher","first-page":"e109","DOI":"10.1097\/AOG.0000000000002588","article-title":"ACOG Committee opinion no. 732: influenza vaccination during pregnancy.","volume":"131","author":"ACOG Committee on Obstetric Practice","year":"2018","journal-title":"Obstet Gynecol"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R51","doi-asserted-by":"publisher","first-page":"177.e1","DOI":"10.1016\/j.ajog.2012.07.007","article-title":"Safety of MF59-adjuvanted A\/H1N1 influenza vaccine in pregnancy: a comparative cohort study.","volume":"207","author":"Heikkinen","year":"2012","journal-title":"Am J Obstet Gynecol"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R52","doi-asserted-by":"publisher","first-page":"4445","DOI":"10.1016\/j.vaccine.2012.04.081","article-title":"A(H1N1)v2009: a controlled observational prospective cohort study on vaccine safety in pregnancy.","volume":"30","author":"Oppermann","year":"2012","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R53","doi-asserted-by":"publisher","first-page":"e2794","DOI":"10.1136\/bmj.e2794","article-title":"Vaccination against pandemic A\/H1N1 2009 influenza in pregnancy and risk of fetal death: cohort study in Denmark.","volume":"344","author":"Pasternak","year":"2012","journal-title":"BMJ"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R54","doi-asserted-by":"publisher","first-page":"e51734","DOI":"10.1371\/journal.pone.0051734","article-title":"Evaluating the hazard of foetal death following H1N1 influenza vaccination; a population based cohort study in the UK GPRD.","volume":"7","author":"Sammon","year":"2012","journal-title":"PLoS One"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R55","doi-asserted-by":"publisher","first-page":"5026","DOI":"10.1016\/j.vaccine.2013.08.097","article-title":"Risks and safety of pandemic H1N1 influenza vaccine in pregnancy: birth defects, spontaneous abortion, preterm delivery, and small for gestational age infants.","volume":"31","author":"Chambers","year":"2013","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R56","doi-asserted-by":"publisher","first-page":"6463","DOI":"10.1016\/j.vaccine.2014.09.054","article-title":"Safety of inactivated monovalent pandemic (H1N1) 2009 vaccination during pregnancy: a population-based study in Taiwan.","volume":"32","author":"Huang","year":"2014","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R57","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1128\/CVI.00375-14","article-title":"Prospective cohort study of the safety of an influenza A(H1N1) vaccine in pregnant Chinese women.","volume":"21","author":"Ma","year":"2014","journal-title":"Clin Vaccine Immunol"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R58","doi-asserted-by":"publisher","first-page":"4443","DOI":"10.1016\/j.vaccine.2016.06.054","article-title":"Safety of the 2010\u201311, 2011\u201312, 2012\u201313, and 2013\u201314 seasonal influenza vaccines in pregnancy: birth defects, spontaneous abortion, preterm delivery, and small for gestational age infants, a study from the cohort arm of VAMPSS.","volume":"34","author":"Chambers","year":"2016","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R59","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1016\/j.vaccine.2015.02.068","article-title":"Influenza vaccination during pregnancy: a systematic review of fetal death, spontaneous abortion, and congenital malformation safety outcomes.","volume":"33","author":"McMillan","year":"2015","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R60","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1093\/cid\/ciu915","article-title":"Maternal influenza immunization and birth outcomes of stillbirth and spontaneous abortion: a systematic review and meta-analysis.","volume":"60","author":"Bratton","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R61","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1097\/AOG.0b013e318279f56f","article-title":"Trivalent inactivated influenza vaccine and spontaneous abortion.","volume":"121","author":"Irving","year":"2013","journal-title":"Obstet Gynecol"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R62","doi-asserted-by":"publisher","first-page":"5314","DOI":"10.1016\/j.vaccine.2017.06.069","article-title":"Association of spontaneous abortion with receipt of inactivated influenza vaccine containing H1N1pdm09 in 2010\u201311 and 2011\u201312.","volume":"35","author":"Donahue","year":"2017","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R63","doi-asserted-by":"publisher","first-page":"6673","DOI":"10.1016\/j.vaccine.2019.09.035","article-title":"Inactivated influenza vaccine and spontaneous abortion in the Vaccine Safety Datalink in 2012\u201313, 2013\u201314, and 2014\u201315.","volume":"37","author":"Donahue","year":"2019","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R64","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1001\/jama.289.2.179","article-title":"Mortality associated with influenza and respiratory syncytial virus in the United States.","volume":"289","author":"Thompson","year":"2003","journal-title":"JAMA"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R65","unstructured":"CDC. Past seasons vaccine effectiveness estimates. Atlanta, GA: US Department of Health and Human Services, CDC. https:\/\/www.cdc.gov\/flu\/vaccines-work\/past-seasons-estimates.html#2021"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R66","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1056\/NEJMoa1315727","article-title":"Efficacy of high-dose versus standard-dose influenza vaccine in older adults.","volume":"371","author":"DiazGranados","year":"2014","journal-title":"N Engl J Med"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R67","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.vaccine.2009.10.037","article-title":"Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccine (TIV) among persons > or =65 years old.","volume":"28","author":"Keitel","year":"2009","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R68","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1056\/NEJMoa1608862","article-title":"Efficacy of recombinant influenza vaccine in adults 50 years of age or older.","volume":"376","author":"Dunkle","year":"2017","journal-title":"N Engl J Med"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R69","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1093\/infdis\/jiw641","article-title":"Comparative effectiveness of high-dose versus standard-dose influenza vaccines among US Medicare beneficiaries in preventing postinfluenza deaths during 2012\u20132013 and 2013\u20132014.","volume":"215","author":"Shay","year":"2017","journal-title":"J Infect Dis"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R70","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1093\/infdis\/jiy716","article-title":"Relative effectiveness of cell-cultured and egg-based influenza vaccines among elderly persons in the United States, 2017\u20132018.","volume":"220","author":"Izurieta","year":"2019","journal-title":"J Infect Dis"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R71","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1093\/infdis\/jiaa080","article-title":"Relative effectiveness of influenza vaccines among the United States elderly, 2018\u20132019.","volume":"222","author":"Izurieta","year":"2020","journal-title":"J Infect Dis"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R72","doi-asserted-by":"publisher","first-page":"e4251","DOI":"10.1093\/cid\/ciaa1727","article-title":"Comparative effectiveness of influenza vaccines among U.S. Medicare beneficiaries ages 65 years and older during the 2019\u201320 season.","volume":"73","author":"Izurieta","year":"2021","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R73","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1093\/infdis\/jiz360","article-title":"Effect of age on relative effectiveness of high-dose versus standard-dose influenza vaccines among US Medicare beneficiaries aged \u226565 years.","volume":"220","author":"Lu","year":"2019","journal-title":"J Infect Dis"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R74","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S1473-3099(14)71087-4","article-title":"Comparative effectiveness of high-dose versus standard-dose influenza vaccines in US residents aged 65 years and older from 2012 to 2013 using Medicare data: a retrospective cohort analysis.","volume":"15","author":"Izurieta","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R75","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S1473-3099(14)71087-4","article-title":"Comparative effectiveness of high-dose versus standard-dose influenza vaccination in community-dwelling veterans.","volume":"61","author":"Richardson","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R76","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1093\/infdis\/jiy088","article-title":"Relative vaccine effectiveness of high-dose versus standard-dose influenza vaccines among Veterans Health Administration patients.","volume":"217","author":"Young-Xu","year":"2018","journal-title":"J Infect Dis"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R77","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1016\/j.vaccine.2019.01.063","article-title":"Analysis of relative effectiveness of high-dose versus standard-dose influenza vaccines using an instrumental variable method.","volume":"37","author":"Young-Xu","year":"2019","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R78","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2020.25.19.1900401","article-title":"High-dose influenza vaccination and mortality among predominantly male, white, senior veterans, United States, 2012\/13 to 2014\/15.","volume":"25","author":"Young-Xu","year":"2020","journal-title":"Euro Surveill"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R79","doi-asserted-by":"publisher","first-page":"446","DOI":"10.3390\/vaccines8030446","article-title":"Evaluating the relative vaccine effectiveness of adjuvanted trivalent influenza vaccine compared to high-dose trivalent and other egg-based influenza vaccines among older adults in the US during the 2017\u20132018 influenza season.","volume":"8","author":"Pelton","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R80","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.vaccine.2019.09.105","article-title":"Comparative effectiveness of high dose versus adjuvanted influenza vaccine: a retrospective cohort study.","volume":"38","author":"van Aalst","year":"2020","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R81","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1016\/j.vaccine.2021.03.054","article-title":"A retrospective cohort study assessing relative effectiveness of adjuvanted versus high-dose trivalent influenza vaccines among older adults in the United States during the 2018\u201319 influenza season.","volume":"39","author":"Pelton","year":"2021","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R82","doi-asserted-by":"publisher","first-page":"4988","DOI":"10.1016\/j.vaccine.2015.07.006","article-title":"Prevention of serious events in adults 65 years of age or older: a comparison between high-dose and standard-dose inactivated influenza vaccines.","volume":"33","author":"DiazGranados","year":"2015","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R83","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1001\/jama.2020.23649","article-title":"Effect of high-dose trivalent vs standard-dose quadrivalent influenza vaccine on mortality or cardiopulmonary hospitalization in patients with high-risk cardiovascular disease: a randomized clinical trial.","volume":"325","author":"Vardeny","year":"2021","journal-title":"JAMA"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R84","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/S2213-2600(17)30235-7","article-title":"Comparative effectiveness of high-dose versus standard-dose influenza vaccination on numbers of US nursing home residents admitted to hospital: a cluster-randomised trial.","volume":"5","author":"Gravenstein","year":"2017","journal-title":"Lancet Respir Med"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R85","doi-asserted-by":"publisher","first-page":"e4237","DOI":"10.1093\/cid\/ciaa1233","article-title":"Cluster-randomized trial of adjuvanted versus nonadjuvanted trivalent influenza vaccine in 823 US nursing homes.","volume":"73","author":"McConeghy","year":"2021","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R86","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1086\/599790","article-title":"Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older.","volume":"200","author":"Falsey","year":"2009","journal-title":"J Infect Dis"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R87","doi-asserted-by":"publisher","first-page":"5027","DOI":"10.1016\/j.vaccine.2014.07.013","article-title":"Comparison of the safety and immunogenicity of an MF59\u00ae-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects.","volume":"32","author":"Frey","year":"2014","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R88","doi-asserted-by":"publisher","first-page":"e2031266","DOI":"10.1001\/jamanetworkopen.2020.31266","article-title":"Safety, reactogenicity, and health-related quality of life after trivalent adjuvanted vs trivalent high-dose inactivated influenza vaccines in older adults: a randomized clinical trial.","volume":"4","author":"Schmader","year":"2021","journal-title":"JAMA Netw Open"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R89","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1080\/21645515.2018.1445446","article-title":"Seasonal influenza vaccine in immunocompromised persons.","volume":"14","author":"Bosaeed","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R90","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1093\/cid\/cit684","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host.","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R91","unstructured":"CDC. Influenza antiviral medications: summary for clinicians. Atlanta, GA: US Department of Health and Human Services, CDC. https:\/\/www.cdc.gov\/flu\/professionals\/antivirals\/summary-clinicians.htm."},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R92","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1093\/cid\/ciu948","article-title":"Allergic reactions after egg-free recombinant influenza vaccine: reports to the US Vaccine Adverse Event Reporting System.","volume":"60","author":"Woo","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R93","doi-asserted-by":"publisher","first-page":"5618","DOI":"10.1016\/j.vaccine.2017.08.047","article-title":"Postmarketing safety surveillance of trivalent recombinant influenza vaccine: reports to the Vaccine Adverse Event Reporting System.","volume":"35","author":"Woo","year":"2017","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R94","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1016\/j.vaccine.2021.02.052","article-title":"Postmarketing safety surveillance of quadrivalent recombinant influenza vaccine: Reports to the Vaccine Adverse Event Reporting System.","volume":"39","author":"Woo","year":"2021","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R95","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1086\/374053","article-title":"Large summertime influenza A outbreak among tourists in Alaska and the Yukon Territory.","volume":"36","author":"Uyeki","year":"2003","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R96","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1086\/429243","article-title":"Influenza virus infection in travelers to tropical and subtropical countries.","volume":"40","author":"Mutsch","year":"2005","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R97","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jcv.2013.01.008","article-title":"Incidence and risk factors for acute respiratory illnesses and influenza virus infections in Australian travellers to Asia.","volume":"57","author":"Ratnam","year":"2013","journal-title":"J Clin Virol"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R98","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/jtm.12215","article-title":"Influenza outbreaks among passengers and crew on two cruise ships: a recent account of preparedness and response to an ever-present challenge.","volume":"22","author":"Millman","year":"2015","journal-title":"J Travel Med"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R99","unstructured":"Flumist Quadrivalent [Package Insert]. Gaithersburg, MD: MedImmune; 2021."},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R100","unstructured":"Rapivab (peramivir for injection) [Package Insert]. Durham, NC: BioCryst; 2017."},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R101","unstructured":"Xofluza (baloxavir marboxil) [Package Insert]. San Francisco, CA: Genentech; 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210854s000lbl.pdf"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R102","unstructured":"Food and Drug Administration. Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products: general considerations. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2003."},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R103","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/S2213-2600(21)00557-9","article-title":"Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged \u226565 years: a phase 2, randomised, open-label study.","volume":"10","author":"Izikson","year":"2022","journal-title":"Lancet Respir Med"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R104","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1111\/j.1532-5415.2007.01397.x","article-title":"Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older.","volume":"55","author":"Kerzner","year":"2007","journal-title":"J Am Geriatr Soc"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R105","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.vaccine.2017.08.029","article-title":"Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine.","volume":"36","author":"Levin","year":"2018","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R106","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1128\/CVI.00176-12","article-title":"Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adults.","volume":"19","author":"Frenck","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R107","doi-asserted-by":"publisher","first-page":"5195","DOI":"10.1016\/j.vaccine.2011.05.031","article-title":"A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged \u226565 years.","volume":"29","author":"Schwarz","year":"2011","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R108","doi-asserted-by":"publisher","first-page":"3464","DOI":"10.1016\/j.vaccine.2006.12.047","article-title":"Comparison of the safety and immunogenicity of concomitant and sequential administration of an adult formulation tetanus and diphtheria toxoids adsorbed combined with acellular pertussis (Tdap) vaccine and trivalent inactivated influenza vaccine in adults.","volume":"25","author":"McNeil","year":"2007","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R109","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1080\/21645515.2018.1455476","article-title":"Immunogenicity of simultaneous versus sequential administration of a 23-valent pneumococcal polysaccharide vaccine and a quadrivalent influenza vaccine in older individuals: A randomized, open-label, non-inferiority trial.","volume":"14","author":"Nakashima","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R110","doi-asserted-by":"publisher","first-page":"4647","DOI":"10.1016\/j.vaccine.2015.05.003","article-title":"Immunogenicity and safety of concomitant MF59-adjuvanted influenza vaccine and 23-valent pneumococcal polysaccharide vaccine administration in older adults.","volume":"33","author":"Song","year":"2015","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R111","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1097\/AOG.0000000000001066","article-title":"Safety of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis and influenza vaccinations in pregnancy.","volume":"126","author":"Sukumaran","year":"2015","journal-title":"Obstet Gynecol"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R112","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1001\/jamapediatrics.2013.4469","article-title":"Risk of fever after pediatric trivalent inactivated influenza vaccine and 13-valent pneumococcal conjugate vaccine.","volume":"168","author":"Stockwell","year":"2014","journal-title":"JAMA Pediatr"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R113","doi-asserted-by":"publisher","first-page":"e20191909","DOI":"10.1542\/peds.2019-1909","article-title":"Fever after influenza, diphtheria-tetanus-acellular pertussis, and pneumococcal vaccinations.","volume":"145","author":"Walter","year":"2020","journal-title":"Pediatrics"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R114","doi-asserted-by":"publisher","first-page":"e20160320","DOI":"10.1542\/peds.2016-0320","article-title":"Febrile seizure risk after vaccination in children 6 to 23 months.","volume":"138","author":"Duffy","year":"2016","journal-title":"Pediatrics"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R115","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1002\/pds.3996","article-title":"Post licensure surveillance of influenza vaccines in the Vaccine Safety Datalink in the 2013\u20132014 and 2014\u20132015 seasons.","volume":"25","author":"Li","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R116","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3928\/00904481-20131122-09","article-title":"Febrile seizures.","volume":"42","author":"Patterson","year":"2013","journal-title":"Pediatr Ann"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R117","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1542\/peds.2007-1064","article-title":"Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age.","volume":"121","author":"Nolan","year":"2008","journal-title":"Pediatrics"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R118","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1016\/j.vaccine.2009.11.054","article-title":"Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young children.","volume":"28","author":"Lum","year":"2010","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R119","unstructured":"Shingrix [Package Insert]. Research Triangle Park, NC: GlaxoSmithKline; 2017."},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R120","unstructured":"Fluad Quadrivalent [Package Insert]. Holly Springs, NC: Seqirus; 2022."},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R121","unstructured":"Heplisav-B [Package Insert]. Emeryville, CA: Dynavax; 2017."},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R122","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1093\/infdis\/jix481","article-title":"Immunogenicity and safety of an adjuvanted herpes zoster subunit vaccine coadministered with seasonal influenza vaccine in adults aged 50 years or older.","volume":"216","author":"Schwarz","year":"2017","journal-title":"J Infect Dis"},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R123","unstructured":"Fluarix Quadrivalent [Package Insert]. Dresden, Germany: GlaxoSmithKline; 2022."},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R124","unstructured":"FluLaval Quadrivalent [Package Insert]. Quebec City, QC, Canada: ID Biomedical Corporation of Quebec; 2022."},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R125","unstructured":"Flucelvax Quadrivalent [Package Insert]. Holly Springs, NC: Seqirus; 2022."},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R126","unstructured":"Fluzone High-Dose Quadrivalent [Package Insert]. Swiftwater, PA: Sanofi Pasteur; 2022."},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R127","unstructured":"Flublok Quadrivalent [Package Insert]. Meriden, CT: Protein Sciences; 2022."},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R128","unstructured":"Food and Drug Administration. Clinical review: Flucelvax Quadrivalent. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2016."},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R129","unstructured":"Food and Drug Administration. Clinical review: Flucelvax Quadrivalent. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; March 2021."},{"key":"key-10.15585\/mmwr.rr7101a1-202208251318-R130","unstructured":"Food and Drug Administration. Clinical review: Flucelvax Quadrivalent. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; October 2021."}],"container-title":["MMWR. Recommendations and Reports"],"original-title":[],"deposited":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T13:45:49Z","timestamp":1661435149000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.cdc.gov\/mmwr\/volumes\/71\/rr\/rr7101a1.htm?s_cid=rr7101a1_w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,26]]},"references-count":130,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,8,26]]}},"URL":"https:\/\/doi.org\/10.15585\/mmwr.rr7101a1","relation":{},"ISSN":["1057-5987","1545-8601"],"issn-type":[{"value":"1057-5987","type":"print"},{"value":"1545-8601","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,8,26]]},"published":{"date-parts":[[2022,8,26]]}}}